CS
AKRO

Credit Suisse’s Akero Therapeutics AKRO Stock Holding History

Credit Suisse’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.18M Buy
46,547
+6,163
+15% +$148K ﹤0.01% 2167
2023
Q4 		$943K Sell
40,384
-2,811
-7% -$55.4K ﹤0.01% 2366
2023
Q3 		$2.18M Sell
43,195
-7,424
-15% -$346K ﹤0.01% 1784
2023
Q2 		$2.36M Buy
50,619
+22,538
+80% +$1.03M ﹤0.01% 1800
2023
Q1 		$1.07M Buy
28,081
+1,442
+5% +$64.3K ﹤0.01% 2281
2022
Q4 		$1.46M Buy
26,639
+13,663
+105% +$585K ﹤0.01% 2072
2022
Q3 		$441K Buy
12,976
+149
+1% +$2.28K ﹤0.01% 2858
2022
Q2 		$122K Buy
12,827
+1,649
+15% +$17.2K ﹤0.01% 3494
2022
Q1 		$159K Buy
11,178
+340
+3% +$5.95K ﹤0.01% 3421
2021
Q4 		$229K Sell
10,838
-19,734
-65% -$438K ﹤0.01% 4226
2021
Q3 		$682K Buy
30,572
+20,235
+196% +$458K ﹤0.01% 3608
2021
Q2 		$256K Sell
10,337
-878
-8% -$24.7K ﹤0.01% 4182
2021
Q1 		$326K Sell
11,215
-17,288
-61% -$523K ﹤0.01% 3971
2020
Q4 		$735K Buy
28,503
+18,624
+189% +$518K ﹤0.01% 3566
2020
Q3 		$304K Buy
+9,879
New +$345K ﹤0.01% 3647

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse's AKRO Position: Q1 2024 in Review

Credit Suisse increased its Akero Therapeutics (AKRO) stake by 15% in Q1 2024, buying an estimated $148K and bringing the position to 46,547 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Credit Suisse first reported a position in AKRO in Q3 2020 and has held it in 15 quarters since. The position peaked at $2.36M in Q2 2023. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

  • Credit Suisse held 46,547 shares of Akero Therapeutics worth $1.18M as of Q1 2024.
  • Credit Suisse bought 6,163 Akero Therapeutics shares in Q1 2024, an estimated $148K.
  • Akero Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2167 holding.
  • Credit Suisse first reported a position in Akero Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Credit Suisse's Akero Therapeutics position peaked at $2.36M in Q2 2023.
  • 173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.